[{"id":"98d3d9bc-9e64-4b61-be85-59f415cfe1f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05573126","created_at":"2022-10-10T14:05:29.537Z","updated_at":"2025-02-25T13:41:17.825Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","source_id_and_acronym":"NCT05573126","lead_sponsor":"Ellipses Pharma","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Orserdu (elacestrant) • vosilasarm (EP0062)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-21"}]